Edition:
India

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

104.09USD
9:37pm IST
Change (% chg)

$0.28 (+0.27%)
Prev Close
$103.81
Open
$104.46
Day's High
$104.50
Day's Low
$103.55
Volume
774,531
Avg. Vol
1,578,192
52-wk High
$104.83
52-wk Low
$59.27

Select another date:

Mon, Jan 8 2018

BRIEF-Abbvie's Upadacitinib Granted Breakthrough Therapy Designation From FDA

* ABBVIE'S UPADACITINIB GRANTED BREAKTHROUGH THERAPY DESIGNATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR ATOPIC DERMATITIS Source text for Eikon: Further company coverage:

U.S. judge tosses verdict against AbbVie in AndroGel case

A U.S. judge on Friday overturned a $150 million verdict against AbbVie Inc that was the first to result from lawsuits claiming that the company fraudulently misrepresented the risks of its testosterone replacement drug AndroGel.

UPDATE 3-U.S. judge tosses verdict against AbbVie in AndroGel case

Dec 22 A U.S. judge on Friday overturned a $150 million verdict against AbbVie Inc that was the first to result from lawsuits claiming that the company fraudulently misrepresented the risks of its testosterone replacement drug AndroGel.

CORRECTED-UPDATE 1-U.S. judge tosses verdict against AbbVie in AndroGel case

Dec 22 A U.S. judge on Friday overturned a $150 million verdict against AbbVie Inc that was the first to result from lawsuits claiming that the company fraudulently misrepresented the risks of its testosterone replacement drug AndroGel.

U.S. judge tosses $150 mln verdict against AbbVie in AndroGel case

Dec 22 A U.S. judge on Friday overturned a $150 million verdict against AbbVie Inc in the first federal court case to go to trial over claims that the company fraudulently misrepresented the risks of its testosterone replacement drug AndroGel.

BRIEF-AbbVie's Upadacitinib Shows Positive Results As Monotherapy In Phase 3 Rheumatoid Arthritis Study

* ABBVIE'S UPADACITINIB SHOWS POSITIVE RESULTS AS MONOTHERAPY IN PHASE 3 RHEUMATOID ARTHRITIS STUDY, MEETING ALL PRIMARY AND KEY SECONDARY ENDPOINTS

BRIEF-Imbruvica Plus Rituximab Phase 3 Innovate Trial In Rare Waldenström's Macroglobulinemia Met Primary Endpoint

* IMBRUVICA® (IBRUTINIB) PLUS RITUXIMAB PHASE 3 INNOVATE TRIAL IN RARE WALDENSTRÖM'S MACROGLOBULINEMIA MET PRIMARY ENDPOINT

BRIEF-Enanta Pharma Says Abbvie’s Maviret ‍is Now Commercially Available In Japan​

* ENANTA PHARMACEUTICALS - ABBVIE'S MAVIRET HAS BEEN APPROVED FOR REIMBURSEMENT BY MINISTRY OF HEALTH, LABOUR AND WELFARE

Roche, AbbVie leukemia drug superior to older medicine in study

Patients with a type of leukemia that had relapsed who received the new drug Venclexta in combination with Rituxan went significantly longer without the disease worsening than those treated with Rituxan and Treanda, according to interim results from a pivotal late stage study released on Tuesday.

Roche, AbbVie leukemia drug superior to older medicine in study

Nov 21 Patients with a type of leukemia that had relapsed who received the new drug Venclexta in combination with Rituxan went significantly longer without the disease worsening than those treated with Rituxan and Treanda, according to interim results from a pivotal late stage study released on Tuesday.

Select another date: